List of Excipients in Branded Drug PRAMOSONE CREAM

Generic Drugs Containing PRAMOSONE CREAM

Company	Ingredient	NDC	Excipient
Sebela Pharmaceuticals Inc	hydrocortisone acetate and pramoxine hydrochloride	54766-716	CETYL ALCOHOL
Sebela Pharmaceuticals Inc	hydrocortisone acetate and pramoxine hydrochloride	54766-716	ISOPROPYL PALMITATE
Sebela Pharmaceuticals Inc	hydrocortisone acetate and pramoxine hydrochloride	54766-716	POLYOXYL 40 STEARATE
Sebela Pharmaceuticals Inc	hydrocortisone acetate and pramoxine hydrochloride	54766-716	POTASSIUM SORBATE

What are the Most Frequently-Used Excipients in PRAMOSONE CREAM?

# Of NDCs	Excipient
2	CETYL ALCOHOL
2	ISOPROPYL PALMITATE
2	POLYOXYL 40 STEARATE
2	POTASSIUM SORBATE

Pramosone Cream Excipient Strategy and Commercial Opportunities

Last updated: August 8, 2026

Pramosone Cream is a topical combination of pramoxine hydrochloride and hydrocortisone used for temporary relief of itching and inflammation associated with corticosteroid-responsive dermatoses. Its commercial opportunity is primarily an improved topical platform rather than protection of a novel active pharmaceutical ingredient. The strongest development paths are better tolerability, reduced mess, improved application, preservative minimization, pediatric usability, and differentiated delivery formats.

Public FDA labeling identifies Pramosone Cream as a topical prescription product containing pramoxine hydrochloride and hydrocortisone acetate. The product is marketed for external use and is not a biologic, injectable, or small-molecule product dependent on a complex manufacturing process. [1]

What is Pramosone Cream used for?

Pramosone Cream combines a topical anesthetic with a corticosteroid.

Attribute	Publicly identified information
Brand	Pramosone Cream
Active ingredients	Pramoxine hydrochloride and hydrocortisone acetate
Dosage form	Topical cream
Therapeutic category	Antipruritic and corticosteroid dermatology product
Route	Cutaneous
Primary commercial use	Temporary relief of itching and inflammation
Prescription status	Prescription topical product in U.S. labeling
Biosimilar relevance	None
Generic substitution risk	Relevant, because the actives are established compounds

Pramoxine provides local anesthetic activity, while hydrocortisone reduces inflammation, redness, and swelling. The combination targets symptomatic relief rather than disease modification. That positioning limits premium pricing unless a successor product delivers measurable advantages in tolerability, adherence, application, or treatment duration.

What excipients are used in Pramosone Cream?

The exact excipient list should be taken from the current approved package insert and the manufacturer’s product documentation. Public labeling for topical pramoxine and hydrocortisone cream products generally identifies a conventional oil-in-water emulsion system containing fatty alcohols, emulsifiers, humectants, solvents, preservatives, and purified water. [1]

The functional excipient architecture is likely to include the following categories:

Excipient function	Typical role in a Pramosone-type cream	Commercial relevance
Emollient	Improves skin feel and reduces dryness	High
Fatty alcohol	Builds cream structure and viscosity	Medium
Emulsifier	Stabilizes oil and water phases	High
Humectant	Maintains hydration and spreadability	High
Solvent or cosolvent	Supports active solubilization	High
Preservative	Controls microbial growth	High for sensitive skin
Chelating agent	Supports preservative and stability performance	Medium
pH adjuster	Maintains active and preservative stability	High
Purified water	Continuous phase of the emulsion	Low
Antioxidant	Protects oxidation-sensitive components	Product-dependent

The key excipient questions are not limited to whether each ingredient is pharmaceutically acceptable. A developer must assess skin irritation, sensitization, preservative burden, microbial robustness, active release, rheology, and compatibility with the selected package.

Which excipients create the greatest differentiation opportunity?

Preservatives, solvents, emulsifiers, and sensory modifiers offer the most practical opportunity.

A conventional cream can cause stinging on excoriated skin if it contains irritating solvents or aggressive surfactants. Fragrance, essential oils, and unnecessary botanical components add limited therapeutic value and may increase sensitization risk. A differentiated product should generally avoid cosmetic fragrance and minimize nonessential sensitizers.

The main excipient opportunities are:

1. A low-irritancy emulsion for compromised or inflamed skin.
2. A preservative-reduced or preservative-free presentation where packaging and microbial controls permit.
3. A non-greasy system with rapid rub-in and low transfer to clothing.
4. A barrier-supportive system containing skin-compatible lipids.
5. A cold-process or low-temperature manufacturing process that reduces degradation risk.
6. A formulation compatible with metered dispensing and unit-dose packaging.

How should an excipient strategy be designed for Pramosone Cream?

The preferred strategy is to optimize the product around the clinical use environment. Patients apply antipruritic corticosteroid creams to irritated, scratched, or barrier-impaired skin. The formulation must therefore balance occlusion, comfort, spreadability, active release, and irritation control.

Emulsion system

An oil-in-water emulsion is generally the most commercially accessible platform for a product intended for repeated application. It provides faster rub-in and lower residue than an ointment. A water-in-oil system could increase occlusion and emolliency, but it may feel greasy and reduce patient preference.

A developer should screen:

• Low-surfactant emulsions.
• Lamellar liquid-crystal systems.
• Polymer-assisted emulsions.
• Silicone-containing systems for improved slip.
• Lipid-replenishing systems for barrier-impaired skin.

The formulation must preserve pramoxine availability in the aqueous phase while maintaining hydrocortisone distribution in the emulsion. Changes in partitioning can alter release and local exposure even when the labeled strength remains unchanged.

Humectants and solvents

Propylene glycol is common in topical products because it can act as a humectant and solvent. It can also sting or irritate some patients, particularly on eroded skin. A reformulated product could evaluate glycerin, pentylene glycol, butylene glycol, or other lower-irritancy solvent systems.

The substitution cannot be based solely on skin feel. The developer must confirm:

• Pramoxine solubility.
• Hydrocortisone stability.
• Preservative efficacy.
• Viscosity and phase stability.
• In vitro release.
• Skin permeation and local retention.
• Container compatibility.

Preservative system

Preservative strategy is a high-value development area. A conventional multidose cream requires strong microbial protection, but some preservatives may create tolerability concerns in dermatology.

Potential paths include:

• A conventional validated preservative system with reduced concentration.
• A synergistic preservative system using chelation and controlled pH.
• An airless pump that reduces repeated environmental exposure.
• Unit-dose sachets or tubes.
• A preservative-free product in a validated container-closure system.

A preservative-free claim requires more than removing a preservative. The product must demonstrate microbiological quality throughout the proposed shelf life and in-use period under applicable FDA expectations. [2]

Skin-barrier excipients

Ceramides, cholesterol, fatty acids, squalane, dimethicone, and selected phospholipids could support a premium positioning. These ingredients may improve dryness and sensory quality, but they also increase formulation complexity and can create new stability or supply-chain risks.

A barrier-supportive Pramosone successor could be positioned for patients with inflamed, dry, or chronically irritated skin. The product would need clinical or instrumental evidence showing an advantage over a conventional cream. Without comparative evidence, barrier ingredients would support marketing language but may not justify a durable price premium.

What formulations are commercially attractive for Pramosone?

The strongest opportunities are adjacent dosage forms rather than a simple duplicate cream.

Product concept	Commercial rationale	Principal technical barrier
Low-irritancy cream	Targets sensitive and excoriated skin	Demonstrating equivalent active performance
Preservative-free cream	Differentiates on tolerability	Microbial control and packaging
Airless-pump cream	Improves hygiene and dosing	Device cost and compatibility
Metered-dose pump	Supports consistent application	Dose uniformity validation
Non-greasy gel-cream	Improves adherence and cosmetic acceptability	Hydrocortisone stability and pramoxine solubilization
Barrier-supportive cream	Adds emollient and skin-care value	Clinical substantiation and cost
Foam or spray	Useful for hairy or difficult-to-reach areas	Aerosol or propellant regulatory complexity
Ointment	Increases occlusion and dryness relief	Greasiness and patient acceptance
Pediatric-oriented presentation	Improves caregiver handling	Safety, dosing, and labeling requirements

Is a gel-cream a viable Pramosone extension?

A gel-cream could be commercially attractive because it may dry faster and reduce clothing transfer. The main challenge is maintaining hydrocortisone stability and achieving adequate pramoxine solubilization without increasing stinging.

Carbomer, acrylate-based polymers, cellulose derivatives, and newer rheology modifiers could create a lighter texture. The selected polymer must be compatible with pH, electrolytes, preservatives, and the active ingredients. Excessive polymer content can reduce active release or create a tacky film.

Is an ointment a viable formulation?

An ointment may benefit patients with severe dryness or fissuring because it provides greater occlusion. It would compete with established corticosteroid and antipruritic ointments, many of which are inexpensive. The opportunity is therefore clinical and sensory, not merely compositional.

A lower-grease ointment using semi-solid hydrocarbons, silicones, or selected esters may offer differentiation, but it would require comparative user testing and stability work.

What FDA regulatory pathway applies to Pramosone Cream?

A reformulated Pramosone product would generally be evaluated through the U.S. drug approval framework for a prescription topical product. The regulatory pathway depends on whether the product is a new drug, an abbreviated application, or a change to an existing approved product.

For a generic version, the applicant would need to address pharmaceutical equivalence and bioequivalence under the applicable FDA standards. Topical products may require comparative in vitro release testing, dermatopharmacokinetic work, clinical endpoint studies, or other evidence depending on the product and FDA guidance. [3]

A materially different formulation may not qualify for a simple generic pathway if the change affects inactive ingredients, release characteristics, tolerability, or local delivery. A new formulation with a distinct clinical benefit could require a 505(b)(2) application, particularly if the applicant relies partly on published or FDA findings for the reference product while introducing a modified dosage form or formulation. [4]

What is the Orange Book status of Pramosone Cream?

Pramosone Cream is subject to the same Orange Book analysis as other prescription drug products, but its commercial patent risk depends on the specific approved product and current listing status. The relevant questions are:

• Whether an approved Pramosone product is listed in the Orange Book.
• Whether any patents are listed for the drug product.
• Whether listed patents cover formulation, method of use, or another approved characteristic.
• Whether pediatric exclusivity, orphan exclusivity, or other regulatory exclusivity applies.
• Whether the listed product remains commercially active.

The active ingredients are old and widely used. The primary risk for a generic or follow-on developer is therefore unlikely to come from composition-of-matter protection. It is more likely to involve formulation equivalence, approval status, manufacturing controls, and any remaining product-specific patents.

FDA’s Orange Book is the controlling source for current patent and exclusivity listings. [5]

When does Pramosone Cream lose exclusivity?

No reliable exclusivity date should be assigned without identifying the exact approved application number and current FDA listing. Pramoxine and hydrocortisone are established active ingredients, so any meaningful exclusivity would generally arise from product-specific formulation, regulatory, or method-of-use rights rather than new chemical entity protection.

For commercial planning, the relevant timeline is:

Exclusivity or protection category	Relevance to Pramosone-type product
New chemical entity exclusivity	Not expected for established actives
Orphan-drug exclusivity	Not apparent for the broad topical indication
Pediatric exclusivity	Must be confirmed in FDA records
Formulation patent	Possible, but requires current patent review
Method-of-use patent	Possible, but likely narrow if present
Manufacturing patent	Potentially relevant to a differentiated delivery system
Trade secret	Relevant to process, scale-up, and preservative control
Trademark	Brand-level protection only

A competitor should not infer freedom to operate from the age of the active ingredients. Formulation patents, packaging patents, and process claims can still create commercial barriers even when the active compounds are off-patent.

What patent protection covers Pramosone Cream?

The commercially relevant patent categories are likely to be:

• Specific concentrations of pramoxine and hydrocortisone.
• Defined weight ratios between the two actives.
• Particular emulsion systems.
• Preservative-free or low-preservative formulations.
• Enhanced skin penetration or local retention.
• Reduced-irritation formulations.
• Metered-dose or airless dispensing systems.
• Treatment of specific dermatologic conditions.
• Manufacturing processes that improve uniformity or stability.

A new entrant should search the USPTO, WIPO Patentscope, Google Patents, and FDA Orange Book using the active ingredients, brand name, manufacturer, formulation terms, and relevant International Patent Classification codes. Patent claims should be reviewed for live status in each target jurisdiction. [5,6]

The strongest potential patent estate would combine composition claims with performance-based claims, such as improved release, reduced irritation, enhanced local retention, or superior stability. A patent that only recites a conventional cream with known excipients is more vulnerable to validity and obviousness challenges.

How strong is the patent estate for Pramosone Cream?

The likely patent position is moderate to weak for the legacy product itself but potentially strong for a genuinely differentiated successor formulation.

Asset	Expected protection strength
Pramoxine composition of matter	Low, because the active is established
Hydrocortisone composition of matter	Low, because the active is established
Basic cream formulation	Low to moderate
Novel low-irritancy excipient system	Moderate
Preservative-free packaging system	Moderate
Metered delivery system	Moderate to strong if technically specific
Demonstrated improved local retention	Stronger if supported by data
Manufacturing process	Moderate, often dependent on enforceability and secrecy
Brand and trade dress	Moderate commercial value, limited substitution control

The best intellectual-property strategy would combine:

1. Composition claims directed to the excipient system.
2. Use claims tied to a defined patient population or treatment setting.
3. Device claims covering dose delivery.
4. Process claims covering emulsion formation or active uniformity.
5. Trade-secret controls for scale-up and preservative validation.

Which companies could challenge or compete with Pramosone Cream?

Competition may come from several groups:

• Generic manufacturers of pramoxine and hydrocortisone combinations.
• Dermatology companies selling hydrocortisone combination products.
• OTC manufacturers selling pramoxine-only antipruritic creams.
• Prescription topical corticosteroid suppliers.
• Consumer-health companies with sensitive-skin and barrier-repair products.
• Compounding pharmacies offering customized strengths or dosage forms.

The closest substitutes are products that provide corticosteroid anti-inflammatory activity, local anesthetic relief, or both. Competition is not limited to identical active ingredients. Physicians and patients may switch to hydrocortisone alone, pramoxine alone, calamine, menthol, diphenhydramine, topical anesthetics, or nonsteroidal anti-inflammatory dermatology products.

What generic entry risks exist for Pramosone Cream?

Generic entry risk is high if the reference product has no meaningful live patent barrier and the market has adequate manufacturing capacity. The principal barriers are regulatory execution and commercial scale.

Key generic-entry risks include:

• Failure to demonstrate equivalent release or local performance.
• Irritation caused by excipient substitution.
• Inadequate preservative efficacy.
• Phase separation or viscosity drift.
• Inconsistent active distribution.
• Tube or pump adsorption.
• Low reimbursement or limited pharmacy substitution.
• Small market size relative to registration and manufacturing costs.

A follow-on applicant can reduce risk by selecting excipients with established topical use, using a package that limits contamination, and designing the formulation around FDA-recognized equivalence methods.

What licensing opportunities exist for Pramosone Cream technology?

The most credible licensing opportunities are platform-based. A licensor could offer:

• A low-irritancy topical emulsion.
• A preservative-free multidose package.
• A metered-dose delivery system.
• A barrier-repair excipient platform.
• A long-shelf-life cream manufacturing process.
• A gel-cream system with validated active release.
• Regional rights for dermatology distribution.

A brand owner may prefer an in-license if the technology improves patient acceptance without requiring a new therapeutic indication. A generic manufacturer may instead seek a formulation partnership that lowers development time and reduces manufacturing change risk.

Licensing value depends on whether the technology produces measurable benefits in release, irritation, stability, adherence, or manufacturing cost. Ingredient novelty alone is unlikely to command a durable premium.

What commercial metrics matter for a Pramosone Cream successor?

Revenue exposure depends on prescription volume, payer reimbursement, channel mix, and the ability to sustain pricing against generic and OTC alternatives. The most important metrics are:

• Units per prescription.
• Net price per gram.
• Refill frequency.
• Gross-to-net discount.
• Pharmacy substitution rate.
• Dermatology versus primary-care prescribing.
• Tube size and average treatment duration.
• Cost of goods per gram.
• Manufacturing yield.
• Stability-related batch failure rate.
• Repeat purchase and discontinuation rates.
• Market share by indication and age group.

A premium product should target a specific unmet need, such as reduced stinging, improved cosmetic acceptability, or easier application. A conventional reformulation without clinical or user evidence will face rapid price erosion.

What geographic opportunities exist for Pramosone Cream?

The United States is the most structured market for patent, Orange Book, and ANDA analysis. Canada, Europe, Japan, Australia, and selected emerging markets may offer separate opportunities, but regulatory classification and approved labeling vary.

Geographic expansion requires review of:

• Local approval status for pramoxine and hydrocortisone combinations.
• Prescription versus nonprescription classification.
• Permitted concentrations.
• Excipient restrictions.
• Required local clinical or equivalence evidence.
• Trademark availability.
• Patent status by country.
• Local manufacturing and import requirements.

A product positioned as a sensitive-skin or barrier-supportive cream may have greater commercial flexibility outside the United States, where dermatology and consumer-health classifications differ.

Key Takeaways

• Pramosone Cream is a topical combination of pramoxine hydrochloride and hydrocortisone acetate.
• Its active ingredients are established, so the main commercial opportunity is formulation and delivery differentiation.
• Low-irritancy emulsions, preservative-reduced systems, airless pumps, metered dosing, and barrier-supportive excipients are the strongest development paths.
• A new formulation must demonstrate active stability, uniformity, microbial control, release performance, and acceptable skin tolerability.
• Orange Book and patent conclusions require review of the exact FDA-listed product and application.
• Generic entry risk is likely to be driven more by regulatory and manufacturing execution than by active-ingredient patents.
• The strongest new IP would combine excipient composition, delivery-device, manufacturing, and performance claims.
• Licensing value will depend on measurable improvement in adherence, tolerability, release, stability, or cost of goods.

FAQs About Pramosone Cream Excipient and Commercial Strategy

Can Pramosone Cream be reformulated without changing its active ingredients?

Yes. A reformulation can retain pramoxine hydrochloride and hydrocortisone acetate while changing the emulsion system, preservative approach, rheology modifier, package, or sensory profile. The regulatory pathway depends on the effect of those changes on equivalence and product performance.

Is a preservative-free Pramosone Cream commercially feasible?

It may be feasible through unit-dose packaging, an airless pump, or another validated container-closure system. The product would still require evidence of microbiological quality, stability, and in-use protection.

Would ceramides create patentable value in Pramosone Cream?

Ceramides alone may not create strong patent protection because they are widely used in dermatology. Patent value would be higher if the formulation produced a defined and demonstrated improvement in stability, active release, skin retention, irritation, or barrier recovery.

Is Pramosone Cream a candidate for OTC conversion?

An OTC strategy would require review of the active ingredients, concentrations, indication, labeling, and applicable FDA monograph or other regulatory pathway. Prescription-to-OTC conversion would also require consumer-use and labeling support.

What is the most attractive successor product to Pramosone Cream?

A low-sting, non-greasy, metered-dose cream with validated active release and barrier-supportive properties is the most commercially differentiated concept. Its value would depend on comparative tolerability, user preference, and reimbursement or pricing evidence.

References

1. DailyMed. (n.d.). Pramosone Cream: Pramoxine hydrochloride and hydrocortisone acetate prescribing information. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (2016). Microbiological quality considerations in non-sterile drug manufacturing.
3. U.S. Food and Drug Administration. (2019). In vitro release test studies for topical drug products submitted in ANDAs: Guidance for industry.
4. U.S. Food and Drug Administration. (2022). Applications covered by section 505(b)(2): Guidance for industry.
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
6. World Intellectual Property Organization. (n.d.). PATENTSCOPE patent search database.